VIR Vir Biotechnology, Inc.
USHealthcareAs of 2026-07-09 16:00
Why VIR matters now
Vir Biotechnology, Inc. (VIR) is a US stock in Healthcare. The latest InvestLog snapshot shows $10.34 with -0.86% on the session and $1.74B in market capitalization; recent performance reads 1-month +7.39% and YTD +51.91%.
The latest financial table shown here is Q1 2026, with revenue of $-29.0K, net income of $-125.7M, and EPS of $-0.85. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -28.8%.
The latest indexable market news headline is "Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors" from Business Wire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $20.00; recent insider activity includes Coughlin Timothy filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.66
P/S
23.59
EV/EBITDA
-3.11
DCF Value
$-72.80
FCF Yield
-28.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
275.2%
Operating Margin
-704.9%
Net Margin
-676.0%
ROE
-53.3%
ROA
-43.2%
ROIC
-48.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $-29.0K | $-125.7M | $-0.85 |
| Q4 2025 | $64.1M | $-42.9M | $-0.31 |
| FY 2025 | $68.6M | $-438.0M | $-3.16 |
| Q3 2025 | $240.0K | $-163.1M | $-1.17 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$21.71
Target (Median)
$20.00
Target Range
$18.00 - $30.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.64
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.